Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

ACURA PHARMACEUTICALS, INC Form 8-K July 28, 2011

# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

**CURRENT REPORT** Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

July 28, 2011 Date of Report (Date of earliest event reported)

# Acura Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

State of New York (State or other jurisdiction of incorporation)

1-10113 (Commission File Number)

11-0853640 (IRS Employer Identification No.)

616 N. North Court, Suite 120 Palatine, Illinois 60067 (Address of principal executive offices) (Zip Code) (847) 705-7709 Registrant's telephone number, including area code:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.42)	5)
--	----

- [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ]
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) [ ]

#### Item 2.02. Results of Operations and Financial Condition.

On July 28, 2011 we issued a press release disclosing the financial results for our second quarter ended June 30, 2011. A copy of our press release is being furnished as Exhibit 99.1 hereto.

#### Item 9.01. Financial Statements and Exhibits.

**Exhibit Number Description** 

гı

## Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

Press Release dated July 28, 2011 Announcing Financial Results for the Second Quarter of 2011

99.1

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### Acura Pharmaceuticals, Inc.

By: /s/ PETER A. CLEMENS

Peter A. Clemens

Date: July 28, 2011 Senior Vice President & Chief Financial Officer

#### **EXHIBIT INDEX**

Exhibit Number	<u>Description</u>
99.1	Press Release dated July 28, 2011 Announcing Financial Results for the Second Quarter of 2011